ABSTRACT
Mutations of the TP53 gene play a role in tumor progression and are likely to provide prognostic information to assist in the management of cancer patients. DNA microarrays for re-sequencing of the TP53 gene offer a promising alternative or supplement to manual Sanger sequencing of DNA extracted from tumors of cancer patients. Recent studies have shown, however, that problems in the analysis of results from the Affymetrix p53 GeneChip limit the accuracy of this method when compared to manual sequencing (Ahrendt et al., 1999; Wikman et al., 2000) .
The Affymetrix p53 GeneChip system includes software for making a difference-based determination of the sequence. Intensities from a chip with an unknown sample are compared to intensities from a chip with a reference, wild-type sequence.
We have trained a neural network of the feed-forward, backpropagation of error type (Baldi and Brunak, 1998) to predict the sequence of the TP53 gene based on the hybridization intensities measured on a single p53 GeneChip. * To whom correspondence should be addressed.
The p53 GeneChip probes each position in the gene with ten oligomers of length 25 nucleotides. The ten oligomers probe for the possible central position A, C, G, T, and deletion on the sense strand, and A, C, G, T, and deletion on the antisense strand.
The optimal neural network design had ten units in the input layer corresponding to the ten chip intensities for each position in the gene. The ten chip intensities were normalized to range from 0 to 1 for each position in the gene. The neural network had a hidden layer of 10-50 units, allowing detection and processing of strong nonlinear correlations between input and output. The output layer had four units, corresponding to a prediction of A, C, G, or T at the position in the gene presented to the input layer.
The neural network was presented with chip intensities from the 1300 positions in the TP53 gene (presented in random order). When trained on seven GeneChips hybridized with wild-type reference TP53 sequence, the neural network was able to predict the sequence of the TP53 gene correctly based on an eighth chip that was not used in training. In an eight-fold cross-validation, the neural network made between zero and four errors in the prediction of the wild-type sequence of 1300 bp.
Training and testing of neural networks based on cancer patient material presents a number of problems. First, no single method, including manual sequencing, can provide a 100% accurate determination of the sequence from an unknown sample (Ahrendt et al., 1999) . Second, the heterogeneity of DNA extracted from cancer tissue often contains a mixture of alleles with differing sequences. As an example, we used DNA extracted from 140 cancer patients and manually sequenced and hybridized to the p53 GeneChip as described previously (Wikman et al., 2000) . Samples with nucleotide deletions were excluded from the set, because the p53 GeneChip does not probe deletions larger than one nucleotide, and because the number of deletions with one nucleotide were too small to allow generalization in our study. In total, we excluded 15 patients, leaving 125. Another neural network was then trained on the 125 patients, which often contain a mixture of wild-type and mutant alleles (Wikman et al., 2000) . The mixed nature of alleles complicated the analysis, as revealed by the fact that the optimal neural network had 50 hidden neurons compared to the 10 hidden neurons that were optimal for predicting the wild-type reference sequence (Figure 1b) . We used as training target the sequence obtained from preliminary manual sequencing of the DNA (Wikman et al., 2000) . Out of the 162 500 examples contained in the 125 patients (each with 1300 positions in their gene) in the training set, there were 51 examples that the network could not learn. When a few examples are inconsistent with all the other examples, the neural network will reveal this inconsistency by an inability to put them in the same category (Brunak et al., 1990) .
We analyzed the unlearnable examples further and found thirteen that lent themselves to testing by Restriction Fragment Length Polymorphism (RFLP) mapping. They were all from position 143 in exon 4 (codon 72) which had been labeled as wild type in the training set and confirmed as such by Affymetrix GeneChip analysis software applied to the same chips. Our neural network predicted a G to C mutation. The mutant and wild-type allele at that position could be distinguished because only the wild-type would form a recognition site, CGCC, for the restriction enzyme BstUI. RFLP mapping was performed on PCR-amplified DNA from the thirteen patients in question. Controls of wild-type DNA were included in the RFLP analysis as well. All thirteen tested patients had a mutation at this position. Going back to the manual sequencing data we could confirm that the mutations were present and in fact corresponded to a well-known polymorphism. Thus, two independent methods verified the discovery of mislabeled data in the training set for the neural network. But it is obvious that such double-determination is very time consuming for a large training set.
In conclusion, we have trained a neural network that can predict the sequence of a homozygous and homogeneous sample of TP53 based on a single chip and tested it on the wild type gene. For mixed samples from patient material where the sequence is not determined with 100% accuracy by a single method, we have shown that already during training, the neural network can detect errors in the labeling of the data. Our method is more sensitive to errors in labeling than the alternative GeneChip method, as shown by a poorer overall performance in prediction on a test set (Figure 1 ). Only when outlier chips were removed from the training set did the performance of the neural network match that of the GeneChip (data not shown). Still, this result shows promise for p53 GeneChips, in combination with neural network processing, as a future diagnostic tool for detecting mutations in the TP53 gene from cancer patients.
